VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of VIZIMPRO (dacomitinib) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the VIZIMPRO (dacomitinib) medicine cost price in India.
The order for VIZIMPRO (dacomitinib) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Dacomitinib was approved in the United States in 2018, in Japan in 2019 and in the European Union (EU) authorized by the European Medicines Agency (EMA) in 2019 for the treatment of non-small cell lung cancer with EGFR gene mutation.
VIZIMPRO® (dacomitinib) for injection, for subcutaneous use. Initial U.S. Approval: 2019
Generic Name: dacomitinib/p>
Tablets: 15 mg, 30 mg, and 45 mg
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand VIZIMPRO (dacomitinib) on prescription and Import License in Patient's Name only.
For overseas patients, VIZIMPRO (dacomitinib) can be made available in Send your enquiry to find VIZIMPRO (dacomitinib) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For VIZIMPRO (dacomitinib) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details